OBJECTIVE to synthesis a new type multi-kinase inhibitor.
目的合成一种新型的多激酶抑制剂。
Is PDGF tyrosine kinase inhibitor effective in pancreatic cancer?
PDGF受体酪氨酸激酶抑制剂在胰腺癌中是否有作用？ ？
Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor.
苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。
The drug - called an Aurora kinase inhibitor - improved survival for mice when combined with chemotherapy.
该药物称为极光激酶抑制剂-改善小鼠化疗时候的存活率。
HNMPA-AM3 -the insulin receptor tyrosine kinase inhibitor could block the anti-apoptosis effect of insulin.
胰岛素受体自身酪氨酸磷酸化抑制剂一一HNMPA一AM3可以阻断胰岛素的抗凋亡作用。
The invention provides methods for the treatment of tyrosine kinase inhibitor resistant cancers with anti-EGFR antibodies.
本发明提供了使用抗egfr抗体治疗抗酪氨酸激酶抑制剂的癌症的方法。
Genistein, a natural tyrosine kinase inhibitor, has been reported to inhibit growth and induce apoptosis of various Turner cells.
金雀异黄素是一种天然的酪氨酸激酶抑制剂，可以抑制多种肿瘤细胞的增殖，并诱发细胞凋亡。
To investigate the effect of benazepril on expression of cyclin kinase inhibitor P21 CIP1 protein in renal tissue of diabetic rats.
目的：探讨苯那普利对糖尿病大鼠肾组织细胞周期蛋白激酶抑制剂p 21 CIP1蛋白表达的影响。
Objective To observe the expression of cyclin kinase inhibitor P16 in pterygium and to investigate its effects on the pathogenesis of pterygium.
目的探讨翼状胬肉组织中细胞周期蛋白依赖性激酶抑制剂P16的表达，了解其在翼状胬肉发病机制中的作用。
PTK787 is the most promising VEGF receptor- tyrosine kinase inhibitor in pipeline because of its potency in tumor inhibition and oral bioavailability.
PTK787因其对肿瘤抑制的出色疗效、口服生物利用度高等特点而成为VEGF受体酪氨酸激酶抑制剂中的佼佼者。
The present invention relates to the treatment of EGFR-mediated disease, particularly cancer, which is resistant to tyrosine kinase inhibitor therapies.
本发明涉及治疗抗酪氨酸激酶抑制剂疗法的EGFR介导的疾病，特别是癌症。
Pretreated with P38 MAP kinase inhibitor SB203580 SHSY5Y cells were exposed to bilirubin, then morphologic change was examined by phase contrast microscope;
用P38激酶抑制剂SB2 0 3580预处理细胞后，在倒置光显微镜下观察胆红素作用不同时间细胞形态的变化及存活情况；
Objective: to investigate the relationship between the cyclin kinase inhibitor P27 and the protective effect of quercetin on the diabetic glomerulus in rats.
目的：探讨槲皮素对糖尿病肾病的影响及该影响与肾小球周期素激酶抑制剂p27的关系。
Conclusion The lower expression of cell circle related kinase inhibitor in pterygium may play an important role on proliferation and pathogenesis of pterygium.
结论翼状胬肉中细胞周期蛋白依赖性激酶抑制剂p16的低表达可能导致翼状胬肉细胞周期紊乱，其增殖失去控制。
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
选择最佳的二线酪氨酸激酶抑制剂治疗伊马替尼治疗失败的慢性粒细胞白细胞患者：BCR - ABL突变状态是否真的重要？
Gefitinib is protein tyrosine kinase inhibitor of a selective EGFR, can block the signal transduction pathway of tyrosine protein kinase, and then promote tumor cell apoptosis.
吉非替尼为一种选择性的EGFR一蛋白酪氨酸激酶抑制剂，能阻断酪氨酸蛋白激酶信号传导通路，从而促进肿瘤细胞凋亡。
Meanwhile, Incyte, a pharmaceutical company in Wilmington, Delaware, presented promising results from a smaller trial of its own kinase inhibitor. And a paper published in September by the.
与此同时，特拉华州威尔明顿的Incyte制药公司，提出了自己的激酶抑制剂小范围试验的良结果。
In the process, Malek noted that mice in which the breakdown of the kinase inhibitor was suppressed by genetic change have a significantly lower risk of suffering from intestinal cancer.
在这个过程中，马利克指出，在其中细分激酶抑制剂是抑制小鼠的遗传变化有一个从患肠癌的风险大大降低。
Rigel's kinase inhibitor, called fostamatinib, targets spleen tyrosine kinase, which among other functions enables the formation of the large immune-cell complexes found in autoimmune diseases.
Rigel的激酶抑制剂，称为fostamatinib，以脾酪氨酸激酶为目标。其主要功能是可以让自身免疫疾病形成大型免疫细胞复合体。
Therefore, the aim of this study is to investigate the effects of genistein, a protein tyrosine kinase inhibitor, on acute and chronic inflammation in diabetic mice (induced by streptozotocin).
因此，本研究的目的是调查金雀异黄素，一种蛋白质酪氨酸激酶抑制剂，对有急性或慢性糖尿病炎症小鼠（诱导脲佐菌素）的影响。
Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC.
索拉非尼是口服的多激酶抑制剂，可以抑制酪氨酸激酶受体，后者促进血管生成并在肾细胞癌中显示出高活性。
The inhibitor of VEGF receptor tyrosine kinase was introduced in detail.
详细介绍了VEGF受体酪氨酸激酶抑制剂的研究进展。
CONCLUSION (Kaempferol is a) novel potent inhibitor of protein kinase CK2 in vitro.
结论山萘黄素是一种新的体外蛋白激酶CK2的有效抑制剂。
Ibrutinib (ibr), a first-in-class, once-daily, oral, covalent inhibitor of Bruton's tyrosine kinase (BTK), is rapidly eliminated from plasma after oral administration (Advani, JCO 2013).
依鲁替尼——首创药物，每天口服一次，布鲁顿酪氨酸激酶（BTK）的共价抑制剂——口服给药之后可快速从浆细胞内清除。
CONCLUSIONS AG1109 not only was an effective inhibitor of protein tyrosine kinases, but also was a novel potent inhibitor of protein kinase CK2.
结论：AG110 9不仅是酪氨酸蛋白激酶的抑制剂，而且是一种十分有效的蛋白激酶CK2的抑制剂。
CONCLUSIONS AG1109 not only was an effective inhibitor of protein tyrosine kinases, but also was a novel potent inhibitor of protein kinase CK2.
结论：AG110 9不仅是酪氨酸蛋白激酶的抑制剂，而且是一种十分有效的蛋白激酶CK2的抑制剂。
应用推荐